GLP-1 Drugs Show Weight Loss Benefits for Seniors but Safety Remains Under Review

Obesity rates among older adults nearly doubled between 1988–1994 and 2015–2018, according to the Population Reference Bureau. Presently, about two in five individuals in this age group are classified as obese based on body mass index (BMI) data from the U.S. Centers for Disease Control and Prevention (CDC).

Obesity is a prominent contributor to numerous age-related health conditions, including cardiovascular disease, type 2 diabetes, and osteoarthritis. Despite this, even modest weight loss can help reduce these risks. Recent studies have demonstrated that GLP-1 drugs are effective for individuals aged 65 and above, showing comparable results to those observed in younger patients.

One study involving 358 participants over 65 years old enrolled in trials of semaglutide, marketed as "Wegovy," found that older adults lost an average of 15.5% of their body weight. This was nearly identical to the 15.6% weight loss observed in younger participants. In contrast, those receiving a placebo lost about 5% of their weight.

Additionally, an analysis of seven randomized controlled trials of tirzepatide, known as "Zepbound," indicated that adults over 65 who received the highest dosage lost an average of 23.3% of their weight. Younger adults in these trials lost 22.6%, while weight loss in the placebo groups ranged between 2% and 4%.

Another comprehensive review published in March by researchers at the Johns Hopkins Bloomberg School of Public Health, which included 64 studies, concluded that the weight loss benefits of GLP-1 drugs were consistent regardless of patient age.

Despite these encouraging findings, experts caution that the evidence remains limited due to relatively small numbers of older participants in clinical trials. Semaglutide studies included 358 individuals aged 65 or older, while tirzepatide trials involved 926 participants over 65, some of whom had type 2 diabetes, which could influence weight loss outcomes.

Dr. John Batsis, a specialist in geriatrics and nutrition at the Gillings School of Global Public Health at the University of North Carolina, noted that most trials either exclude older adults or include very few, especially those over 75. He emphasized that physiological differences in this group make it inappropriate to generalize findings from younger populations.

Dr. Jennifer Schrack, director of the Center on Aging and Health at Johns Hopkins Bloomberg School of Public Health, stated that knowledge about GLP-1 drugs is still in early stages. She warned that older adults might lose muscle mass along with fat, potentially increasing the risk of falls and fractures, particularly in those with poor balance or low bone density. She stressed the importance of resistance or weight training exercises alongside medication use.

Side Effects and Risks in Older Adults

In clinical trials, participants aged 65 and above taking GLP-1 medications experienced some side effects more frequently than those aged 18 to 64. In tirzepatide studies, gastrointestinal issues caused 7% of older participants to discontinue treatment. Approximately 25% reported nausea, about 20% experienced diarrhea or constipation, and around 10% had vomiting episodes.

These rates were similar to those seen in younger adults, but experts warn the consequences may be more severe for older individuals. Aging reduces the sensation of thirst, complicating hydration maintenance. Vomiting or slowed digestion can quickly lead to dehydration, which may cause kidney problems or intestinal blockages.

Some concerns related to GLP-1 drugs remain theoretical. Dr. Batsis explained that weight loss involves losing fat, muscle, and bone, but loss of muscle mass does not necessarily equate to reduced functional ability. Clinical trials have not shown a clear increase in falls or fractures. In tirzepatide trials, fall risk was nearly the same as placebo, and some fractures decreased. Semaglutide results showed a similar trend, with slightly fewer bone and joint injuries among users, although a marginally higher fall rate was recorded (4.4% versus 3.6% in placebo).

Guidance for GLP-1 Medication Use in Seniors

First, consult your healthcare provider. Dr. Melanie Jay, director of the comprehensive obesity treatment program at NYU Langone Medical Center, emphasized the need for regular medical monitoring, especially at treatment initiation. She noted that older adults might benefit most, as these drugs can reduce heart attack and cardiovascular death risk by up to 20% over four years in patients with heart disease. However, she highlighted the importance of careful follow-up in this population.

Second, maintain adequate hydration. Dr. Allison Moore, a geriatric and internal medicine specialist at the University of California, San Diego, advises patients on GLP-1 drugs to drink sufficient water. Many older adults experience mild to moderate dehydration due to diminished thirst sensation. She recommends consuming a glass of water with every meal—ideally two or more glasses—and drinking most fluids earlier in the day to avoid nighttime bladder disturbances.

Proper hydration may also alleviate constipation, a common side effect among older adults using GLP-1 drugs. In tirzepatide trials, about 19% of older participants reported constipation compared to approximately 6% in placebo groups.

Third, seek nutritional counseling. Dr. Jay pointed out that certain diets may exacerbate side effects, making accurate dietary information and professional advice essential. She explained that fatty, fried foods and large meals can trigger nausea and vomiting. Conversely, she stressed the importance of protein intake to preserve muscle mass. Since GLP-1 medications promote early satiety, she recommends starting meals with protein followed by fruits and vegetables to ensure adequate nutrient consumption.

Finally, set realistic goals. Dr. Batsis advised shifting focus away from weight alone toward enhancing functional capacity in older adults. He noted that weight loss not only extends lifespan but also improves quality of life by reducing joint pain and facilitating mobility. However, he cautioned against excessive weight loss.